Federal agencies have spoken to pharmaceutical companies to let them know their RSV immunizations and therapies were going to see new scrutiny. Specifically, the companies involved are Merck, Sanofi and AstraZeneca, and their FDA-approved immunizations will have their safety data reviewed again, despite have gone through this exact process in recent years.
This continues as Health and Human Services Secretary Robert F Kennedy aims to review all vaccines and reduce greatly access to such immunizations.
The FDA’s drug division is “rigorously reviewing the available data, as it does for all products,” HHS spokesman Andrew Nixon said. “FDA routinely evaluates emerging safety information and will update product labeling if warranted by the totality of the evidence.”2
In a previous interview with Contagion, Helen Chu, MD, MPH, offers some insights on the previous burden of RSV prior to the immunizations, and the efficacy of 2 RSV products in preventing disease.